Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Vivus reports results from phase III avanafil study in erectile dysfunction

Nov. 19, 2009

Favorable safety and lipid profiles with anacetrapib therapy in hyperlipidemia

Nov. 19, 2009

Glucokinase activators for the treatment of diabetes described by Merck KGaA

Nov. 18, 2009

Genzyme receives FDA complete response letter on Lumizyme marketing application

Nov. 17, 2009

Esperion Therapeutics initiates phase I ETC-1002 trial in healthy volunteers

Nov. 17, 2009

Aegerion reports additional lomitapide phase III data

Nov. 17, 2009

FDA approves Lysteda for the treatment of menorrhagia

Nov. 17, 2009

Spherix reports interim results of phase III trial of D-tagatose in diabetes

Nov. 17, 2009

Diamyd Medical completes enrollment in a phase III trial of Diamyd

Nov. 16, 2009

FYX-051 shows potent serum uric acid-lowering activity in rats

Nov. 16, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....